FDA Approves Selpercatinib for RET Fusion+ Medullary Thyroid Cancer

Fact checked by Russ Conroy
News
Article

The FDA granted traditional approval to selpercatinib for patients with advanced or metastatic medullary thyroid cancer with a RET mutation.

FDA

Support for the regulatory decision came from the multicenter, open-label LIBRETTO-531 trial (NCT04211337).

The FDA granted traditional approval to selpercatinib (Retevmo) for the treatment of adult and pediatric patients at least 2 years old with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.1

Support for the regulatory decision came from the multicenter, open-label LIBRETTO-531 trial (NCT04211337), which showed that the median progression-free survival was not reached (NR; 95% CI, NE) in patients who were randomly assigned to selpercatinib vs 16.8 months (95% CI, 12.2-25.1) for those who were treated with cabozantinib (Cabometyx) or vandetanib (Caprelsa; HR, 0.280; 95% CI, 0.165-0.475; P <0.0001).

The FDA initially granted accelerated approval to selpercatinib for this indication in patients aged at least 12 years old in 2020. An accelerated approval for the agent was granted in May 2024 to pediatric patients aged 2 years and older.

Reference

  1. FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer. FDA. News release. September 27, 2024. Accessed September 27, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-ret-fusion-positive-medullary-thyroid-cancer
Recent Videos
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
Related Content